Competitor Mapping
Competitor portfolios mapped and compared
RGS combines authorisations, pending filings, tender awards and supply relationships into one view of each competitor: what they hold, where they are expanding, what they are developing, who makes it for them and where they win. Changes are flagged as they happen.
How it works
How Competitor Mapping works
Combine
Authorisations, pending applications, tender awards and manufacturing links joined at company-group level.
Compare
Portfolios compared molecule by molecule and market by market against yours.
Watch
New holdings, filings, wins and supplier changes flagged as they appear.
Competitor Mapping
One view of each competitor, from four kinds of evidence
Portfolio, pipeline, tender record and supply partners on one page per company, kept current.
- Portfolio overlap with yours
- Pipeline by molecule and market
- Tender wins and prices by market
Competitor Mapping
From a map to a decision
Choose markets, plan launches around known entrants, screen partners or brief the board.
- White space by molecule and market
- Partner and licensing screening
- Board-ready competitor briefs
Questions
Questions about Competitor Mapping
How many generic competitors are there per molecule and country?
RGS counts the holders with a valid authorisation, those with a pending application and those that actually bid in tenders, per molecule and country. The three numbers often differ, and the gap shows who is ready to enter.
What does competitor mapping in pharma include?
At RGS it combines four kinds of evidence: marketing authorisations, pending applications, tender awards and manufacturing links. Together they show what each competitor holds, what it is developing, where it wins and who supplies it.
Works with
Award and Price Intelligence
Who won each tender, the published bid prices by strength, and how far off you were.
Explore Regulatory intelligenceFiling Radar
Pending applications: who is coming, and when they may sell.
Explore Regulatory intelligenceMAH Tracking
Granted licences: who holds each molecule today, and what changed.
ExploreSee competitor mapping on your own molecules
Send us your portfolio and markets. We will show you what the data says before the call.